Trial Profile
An open-label, ascending-dose, clinical trial of intra-arterial microplasmin administration in patients with acute peripheral arterial occlusion
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2018
Price :
$35
*
At a glance
- Drugs Ocriplasmin (Primary)
- Indications Arterial occlusive disorders
- Focus Therapeutic Use
- Sponsors Oxurion
- 17 Nov 2008 Actual patient number (19) added as reported by ClinicalTrials.gov.
- 23 Oct 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Apr 2008 New trial record.